Hostname: page-component-848d4c4894-wzw2p Total loading time: 0 Render date: 2024-05-16T04:12:20.393Z Has data issue: false hasContentIssue false
  • English
  • Français

Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial

Published online by Cambridge University Press:  19 July 2023

U. Nitzan
U. Nitzan*
Affiliation:
Shalvata Mental Health Center and Tel-Aviv University, Tel-Aviv, Israel

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The response to placebo is robust in studies of various antidepressant treatments. The strong placebo response, combined with the absence of side-effects, has prompted suggestions to use the ethically sound open-label placebo (OLP) as a treatment for depression.

Objectives

The aim of the present study was to assess the efficacy of OLP in the setting of a randomized controlled trial for the treatment of unipolar depression.

Methods

Thirty-eight patients (28 females, 73.7%) were randomized to either an eight-week treatment with OLP (n=18) or four week of treatment as usual (TAU) followed by four weeks of OLP (n=20). Clinical and socio-demographic measures were assessed at baseline, after four weeks, and at the end of the trial. Response to treatment was determined using the Quick Inventory of Depressive Symptomatology (QIDS SR-16).

Results

There was an overall decrease in depression levels over time, F(2,35) = 3.98, p = .028). A significant group x time interaction was found only among non-geriatric patients (<65y) with an early onset of depression (<50y), F(2,22) = 3.89, p = .036]. Post-hoc tests indicated a significant decrease during the first four weeks, but only in the OLP group, t(11) = 2.29, p = .043.Table 1:

Demographic measures of OLP and TAU patients.

MeasuresOLP (n = 18)TAU (n =20)Statistical analyses
Age (years) [Mean ± SD]48.17 ± 16.8651.65 ± 17.68t(36) = -0.62, p = .539
Education level (years) [Mean ± SD]15.61 ± 3.6614.22 ± 2.62t(34) = 1.31, p = .200
Gender (male/female) [no.]4 / 146 / 14X2(1) = 0.30, p = .587
Age of onset (years) [Mean ± SD]34.19 ± 15.8232.45 ± 17.72t(36) = 0.32, p= .752
Number of depressive episodes (no.) [Mean ± SD]2.58 ± 2.616.64 ± 9.16t(21) = -1.47, p = .156
Number of hospitalizations (no.) [Mean ± SD]0.12 ± 0.330.17 ± 0.38t(33)= -0.40, p = .689

Notes

OLP = Open label placebo; SD = Standard deviation; TAU = Treatment as usual.

Image 3:

Conclusions

Our findings support the possibility that OLP is an effective treatment for the relatively young population of patients suffering from depression. Additional studies are warranted in order to explore the use of open-label placebo in clinical work.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S845 - S846
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.